TD Cowen Maintains Syros Pharmaceuticals(SYRS.US) With Hold Rating
Syros Pharmaceuticals Cut to Market Perform From Market Outperform by JMP Securities
Syros Pharmaceuticals Analyst Ratings
JMP Securities Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating
TD Cowen Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating
Brookline Capital Downgrades Syros Pharmaceuticals(SYRS.US) to Hold Rating
Syros Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Maintains Target Price $6
TD Cowen Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating
JMP Securities Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Cuts Target Price to $4
Piper Sandler Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Cuts Target Price to $5
Piper Sandler Remains a Buy on Syros Pharmaceuticals (SYRS)
TD Cowen Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating
Piper Sandler Keeps Their Buy Rating on Syros Pharmaceuticals (SYRS)
Syros Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Cuts Target Price to $6
Syros Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Maintains Target Price $12
Buy Rating Affirmed for Syros Pharmaceuticals Amid Anticipated Clinical Trials and Strong Financials